Literature DB >> 16360003

Molecular mechanisms in cancer: what should clinicians know?

Jaffer Ajani1, Victoria Allgood.   

Abstract

Normal cells are influenced by a variety of environmental and host influences that can produce pro-carcinogenic mutations. Either a single or a series of mutations might result in cellular transformation. Like normal cells, most cancer cells use multiple redundant intracellular signaling pathways to ensure the maintenance and viability of functions critical to their survival. Thus, cellular pathways that are integral to cell function, survival, proliferation, and receptor expression are potential targets for therapeutic intervention. One example of this is the epidermal growth factor receptor signaling pathway. Other potential targets are molecules that mediate processes through which tumors produce angiogenic and invasion factors that stimulate host blood vessel growth into tumors and allow tumor growth and metastasis, such as the vascular endothelial growth factor. Targeting of downstream events that result in cellular apoptosis is another potential strategy. Continued investigations may result in the development of proteomic profiling databases through which a patient might be matched with molecular signatures in a library and upon which individualized cancer therapies might be selected. In this way, clinicians might recommend combinations of molecularly targeted agents and other therapies on the basis of an individual patient's proteomic profile.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16360003     DOI: 10.1053/j.seminoncol.2005.07.016

Source DB:  PubMed          Journal:  Semin Oncol        ISSN: 0093-7754            Impact factor:   4.929


  7 in total

1.  Cutaneous melanoma in situ: translational evidence from a large population-based study.

Authors:  Simone Mocellin; Donato Nitti
Journal:  Oncologist       Date:  2011-05-31

2.  Analysis of the correlation among hypertension, the intake of β-blockers, and overall survival outcome in patients undergoing chemoradiotherapy with inoperable stage III non-small cell lung cancer.

Authors:  Pei Yang; Weiye Deng; Yaqian Han; Yingrui Shi; Ting Xu; Juan Shi; Hesham Elhalawani; Yu Zhao; Xiaoxue Xie; Fan Lou; Rong Zhang; Hekun Jin
Journal:  Am J Cancer Res       Date:  2017-04-01       Impact factor: 6.166

3.  Emerging technologies for the genomic analysis of cancer.

Authors:  John Nemunaitis; Neil N Senzer
Journal:  F1000 Biol Rep       Date:  2009-05-08

Review 4.  Uncovering Pandora's vase: the growing problem of new toxicities from novel anticancer agents. The case of sorafenib and sunitinib.

Authors:  C Porta; C Paglino; I Imarisio; L Bonomi
Journal:  Clin Exp Med       Date:  2008-01-11       Impact factor: 3.984

Review 5.  Contribution of oncoproteomics to cancer biomarker discovery.

Authors:  William C S Cho
Journal:  Mol Cancer       Date:  2007-04-02       Impact factor: 27.401

6.  A large-scale retrospective study of the overall survival outcome in nasopharyngeal carcinoma with hypertension in Chinese population.

Authors:  Pei Yang; Hesham Elhalawani; Yingrui Shi; Ying Tang; Yaqian Han; Yu Zhao; Fan Lou; Hekun Jin
Journal:  Oncotarget       Date:  2017-04-27

7.  Glycosylated VCAM-1 isoforms revealed in 2D western blots of HUVECs treated with tumoral soluble factors of breast cancer cells.

Authors:  Delina Montes-Sánchez; Jose Luis Ventura; Irma Mitre; Susana Frías; Layla Michán; Aurora Espejel-Nuñez; Felipe Vadillo-Ortega; Alejandro Zentella
Journal:  BMC Chem Biol       Date:  2009-11-22
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.